Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

The Joint Blog

MARCH 18, 2021

According to a new study titled Use of cannabinoids for the treatment of patients with post-traumatic stress disorder, the consumption of cannabinoids and cannabinoid products is safe and effective in the mitigation of symptoms of post-traumatic stress (PTS). Additional information on cannabis and PTSD is available from NORML.

Cannabinoids 26

Cannabinoids Patients Clinical Trials Research and Development 26

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

The Joint Blog

APRIL 17, 2020

Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. 2 Types of THC Impact THC has broad pharmacological spread which means there are many opportunities for is to cause adverse Drug Events or unpredictable drug-drug interactions.

Events 48

Events THC Chronic Pain Sleep 48

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 24, 2019

Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis. The approval of cannabidiol oral solution is based on results from four randomised, controlled Phase 3 trials. LONDON and CARLSBAD, Calif., In June 2018 GW, along with its U.S.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

NOVEMBER 12, 2021

Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 12, 2021

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 108

Programs Research and Development Education Treatment 108

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. a heart attack).

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

Green Relief

MAY 13, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek will thoroughly control, analyse and optimise every step of its production to ensure the quality of the finished product using climatic and cultivation data combined with patient data, gathered in house. Cannatrek is actively working on clinical trial protocols with a dedicated focus on mental health.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Green Relief

MAY 12, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. This offers a more denotative approach to complement the data.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JANUARY 18, 2019

Schedule of Events: Tuesday Jan 22nd 4-6:00 pm. CannaTech is the only Medical Cannabis event of its kind with a global focus that offers senior industry leaders, medical and scientific experts, and new ventures the platform to come together, drive innovation, form partnerships and promote knowledge exchange. Welcoming Remarks.

Research and Development 40

Research and Development Clinical Trials Extraction Therapy 40

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Science also announced a new CTO, Sheldon Borkin , PhD, who joined in September 2021.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. in/rickdoblin/ [link]. in/ingmargorman/ [link]. in/gpechenik/ [link]. James Keim. Mimosa Therapeutics. James Keim is a psychotherapist.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 17, 2019

THC is just one of the cannabinoids in the Cannabis sativa L. The other major cannabinoid of particular interest commercially is cannabidiol (CBD). All told, the global legal cannabis industry, including dried cannabis and products containing cannabinoids, was estimated at US $11.9

Law 40

Law Seed-To-Sale Hemp Recreational 40

NORML

SEPTEMBER 20, 2019

But at the Vegas event, she brought good news: She announced that other universities would host her research, and she recently applied for a third-party cultivation license from the DEA, the only federal agency that can legally provide cannabis for clinical study in the US. It was just diluted with a lot of extraneous plant material.

DEA 231

DEA Research and Development Clinical Trials Patients 231